Lymphoma and CLL highlights of the ASH 2025

Catherine S. Diefenbach discusses the lymphoma and CLL highlights at the American Society of Hematology's 67th Annual Meeting.

Available Research Guiding the Selection of Therapy for Patients with Chronic Lymphocytic Leukemia

Matthew S. Davids discusses the available research guiding the selection of therapy for patients with chronic lymphocytic leukemia at the American Society of Hematology's 67th Annual Meeting.

Novelties in Acute Myeloid Leukemia at ASH2025

Mark Levis discusses the novelties in acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.

What's new in myeloma?

Enrique Ocio discusses what's new in multiple myeloma treatement at the American Society of Hematology's 67th Annual Meeting.

Azacitidine–Venetoclax Combination Outperforms Standard Care in Acute Myeloid Leukemia Patients Eligible for Intensive Chemotherapy

Amir Fathi discusses the results from a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia at the American Society of Hematology's 67th Annual Meeting.

Symptom-based progression-free survival as a clinically relevant and patient-centric endpoint in chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the ALPINE trial

Jennifer R. Brown explains the results from the ALPINE trial at the American Society of Hematology's 67th Annual Meeting.

Validation of measurable residual disease as a surrogate endpoint in acute myeloid leukemia: A HARMONY Alliance study of European randomized trials

Jesse Tettero discusses the results from the HARMONY Alliance study at the American Society of Hematology's 67th Annual Meeting.

Primary efficacy analysis of TKI and inotuzumab ozogamicin-based therapy for newly diagnosed Ph+ ALL

Anand A. Patel discusses the primary efficacy analysis of a Phase II study investigating tyrosine kinase inhibitor and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukemia at the American Society of Hematology's 67th Annual Meeting.

Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL

Jennifer Woyach discusses the noncovalent BTK inhibitor pirtobrutinib achieved noninferiority to the covalent BTK inhibitor ibrutinib in terms of overall response rate in patients with CLL or SLL, according to findings from a randomized phase III trial presented at the American Society of Hematology's 67th Annual Meeting.

Quadruplet Therapy in Multiple Myeloma

Rahul Banerjee discusses the quadruplet therapy in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Novelties in Diffuse Large B-cell Lymphoma at ASH2025

Joshua Brody discusses the novelties in diffuse large B-cell lymphoma at the American Society of Hematology's 67th Annual Meeting.

Breakthrough in the treatment of Multiple Myeloma

Xavier Leleu explains the breakthrough in the treatment of multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Diagnosis and Management of Cold Agglutinin Disease

Sigbjorn Berentsen discusses the diagnosis and management of cold agglutinin disease at the American Society of Hematology's 67th Annual Meeting.

Multiple Myeloma Highlights from ASH 2025

Paul G Richardson discusses multiple myeloma highlights at the American Society of Hematology's 67th Annual Meeting.

COBRA trial and other novelties in multiple myeloma at ASH 2025

Andrzej Jakubowiak discusses the COBRA trial and other novelties in multiple myeloma at the American Society of Hematology's 67th Annual Meeting.

Myelodysplastic Syndrome Highlights from ASH 2025

Mikkael A. Sekeres discusses the state of the art treatment in myelodysplastic syndrome at the American Society of Hematology's 67th Annual Meeting.

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study: A Perioperative Management Plan for Patients with Atrial Fibrillation Who Are Receiving a Direct Oral Anticoagulant

Safety and Efficacy of Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis

A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy Vs. Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL): A Trial of the ECOG-ACRIN Cancer Research Group (E1912)

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant (MAIA)

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Best of ASH

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes

Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies

Multicenter Microbiota Analysis Indicates That Pre-HCT Microbiota Injury Is Prevalent across Geography and Predicts Poor Overall Survival

Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI)